BR112017019920A2 - preparação sólida farmacêutica, e, método para estabilização de uma preparação sólida farmacêutica - Google Patents

preparação sólida farmacêutica, e, método para estabilização de uma preparação sólida farmacêutica

Info

Publication number
BR112017019920A2
BR112017019920A2 BR112017019920-3A BR112017019920A BR112017019920A2 BR 112017019920 A2 BR112017019920 A2 BR 112017019920A2 BR 112017019920 A BR112017019920 A BR 112017019920A BR 112017019920 A2 BR112017019920 A2 BR 112017019920A2
Authority
BR
Brazil
Prior art keywords
tablet containing
solid tablet
containing colorant
ethylbicyclo
hept
Prior art date
Application number
BR112017019920-3A
Other languages
English (en)
Japanese (ja)
Other versions
BR112017019920B1 (pt
Inventor
Tajiri Shinichiro
Yoshinaga Shinji
Ozaki Yurika
Original Assignee
Daiichi Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Company, Limited filed Critical Daiichi Sankyo Company, Limited
Publication of BR112017019920A2 publication Critical patent/BR112017019920A2/pt
Publication of BR112017019920B1 publication Critical patent/BR112017019920B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

o objetivo é prover um medicamento no qual sulfonato monobenzeno de ácido acético [(1r,5s,6s)-6-(aminometil)-3-etilbiciclo[3.2.0]hept-3-en-6-ila] é estabilizado e prover um método para preparar a preparação sólida farmacêutica. a solução é um composto tendo a seguinte fórmula [(1r,5s,6s)-6-(aminometil)-3-etilbiciclo[3.2.0]hept-3-en-6-ila] um ou mais selecionados do grupo que consiste em d-manitol, lactose, amido de milho e celulose de cristal, (ii) carmelose cálcio e (iii) um colorante.
BR112017019920-3A 2015-03-19 2016-03-17 Preparação sólida farmacêutica, e, método para estabilização de uma preparação sólida farmacêutica BR112017019920B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015055769 2015-03-19
JP2015-055769 2015-03-19
PCT/JP2016/058608 WO2016148264A1 (ja) 2015-03-19 2016-03-17 着色剤を含有する固形製剤

Publications (2)

Publication Number Publication Date
BR112017019920A2 true BR112017019920A2 (pt) 2018-06-19
BR112017019920B1 BR112017019920B1 (pt) 2023-11-07

Family

ID=56918974

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017019920-3A BR112017019920B1 (pt) 2015-03-19 2016-03-17 Preparação sólida farmacêutica, e, método para estabilização de uma preparação sólida farmacêutica

Country Status (10)

Country Link
US (1) US10603285B2 (pt)
EP (3) EP3513788B1 (pt)
JP (1) JP6630344B2 (pt)
KR (1) KR102401145B1 (pt)
CN (1) CN107427483B (pt)
BR (1) BR112017019920B1 (pt)
CA (1) CA2980097C (pt)
ES (1) ES2821733T3 (pt)
TW (1) TWI717339B (pt)
WO (1) WO2016148264A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102401145B1 (ko) 2015-03-19 2022-05-23 다이이찌 산쿄 가부시키가이샤 착색제를 함유하는 고형 제제
JP6630343B2 (ja) * 2015-03-19 2020-01-15 第一三共株式会社 抗酸化剤を含有する固形製剤
KR102169466B1 (ko) 2016-01-05 2020-10-26 그레이스노트, 인코포레이티드 채널 변화 기반 트리거 피처를 갖는 컴퓨팅 시스템
EP3831373B1 (en) * 2018-07-30 2023-03-15 Daiichi Sankyo Company, Limited Stabilizer-containing solid drug formulation
CN110742868A (zh) * 2019-11-20 2020-02-04 合肥拓锐生物科技有限公司 一种Mirogabalin Besilate口腔崩解片
CN110917164B (zh) * 2019-12-17 2022-03-29 南京康川济医药科技有限公司 一种苯磺酸米洛巴林缓释片及其制备方法
JP6993765B2 (ja) * 2019-12-23 2022-02-07 第一三共株式会社 滑らかな表面を有するフィルムコーティング錠
BR112023000403A2 (pt) 2020-07-27 2023-02-07 Daiichi Sankyo Co Ltd Comprimido de desintegração oral, e, método para produzir um comprimido de desintegração oral

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY100306A (en) * 1985-12-18 1990-08-11 Kao Corp Anti-suntan cosmetic composition
DE3928183A1 (de) 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
PT948965E (pt) 1997-07-11 2004-08-31 Toray Industries Composicoes medicinais estaveis contendo um derivado de 4,5-epoximorfinano
JPH11189547A (ja) 1997-12-26 1999-07-13 Taisho Pharmaceut Co Ltd 安定化されたニコランジル製剤及びその製造方法
KR100507400B1 (ko) * 1999-08-04 2005-08-10 아스텔라스세이야쿠 가부시키가이샤 안정한 경구용 의약 조성물
JP2001064177A (ja) 1999-08-16 2001-03-13 Schering Ag ベンズアミド誘導体を有効成分とする製剤
DE60025750T2 (de) 1999-11-11 2006-10-19 Kyorin Pharmaceutical Co., Ltd. Orale feste zusammensetzung
MY136633A (en) * 2001-01-17 2008-11-28 Berlin Chemie Ag Stabilized brivudine topical formulations
JP2003104887A (ja) 2001-09-28 2003-04-09 Maruko Seiyaku Kk 光に安定なアラニジピン含有組成物
ZA200409537B (en) 2003-01-31 2006-10-25 Yamanouchi Pharma Co Ltd Stable solid medicinal composition for oral administration
JP4783573B2 (ja) 2004-02-20 2011-09-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 ワルファリンカリウム含有医薬組成物とその製造方法
KR20060135853A (ko) * 2004-04-08 2006-12-29 교와 핫꼬 고교 가부시끼가이샤 디벤조[ｂ,ｅ]옥세핀 유도체를 함유하는 고형제
WO2006056874A1 (en) 2004-11-25 2006-06-01 Pfizer Limited Salt form
CN101300010B (zh) 2005-10-31 2012-06-06 兴和株式会社 光稳定性优异的医药制剂
PE20070702A1 (es) 2005-11-02 2007-07-20 Takeda Pharmaceutical COMPUESTOS DERIVADOS DE (TRIFLUOROMETOXI-FENIL)-ETILAMINO COMO INHIBIDORES DE LA ACETILCOLINESTERASA Y ANTAGONISTAS DEL RECEPTOR DE ADRENALINA alfa1
JP4691434B2 (ja) 2005-11-08 2011-06-01 東和薬品株式会社 安定化されたカベルゴリン固形製剤
CA2662938A1 (en) * 2006-09-15 2008-03-20 Astellas Pharma Inc. Light-stable solid pharmaceutical composition of ramosetron
PT2192109E (pt) 2007-09-28 2013-12-09 Daiichi Sankyo Co Ltd Derivado de -aminoácido bicíclico
JP5558023B2 (ja) 2008-04-18 2014-07-23 第一三共株式会社 医薬品組成物
CA2734847C (en) 2008-08-18 2016-08-30 Mitsubishi Shoji Foodtech Co., Ltd. Novel excipient for mannitol tableting
CN102300563A (zh) * 2009-01-29 2011-12-28 大日本住友制药株式会社 具有内核的口腔崩解片剂
JP2010241796A (ja) 2009-03-17 2010-10-28 Daiichi Sankyo Co Ltd 二環性γ−アミノ酸誘導体含有医薬組成物
CN102356061B (zh) 2009-03-26 2014-02-19 第一三共株式会社 用于制备二环γ-氨基酸衍生物的方法
US9446055B2 (en) 2009-08-11 2016-09-20 Fuji Chemical Industry Co., Ltd. Disintegrating particle composition and orally rapidly disintegrating tablet
WO2011051968A2 (en) 2009-10-26 2011-05-05 Alkem Laboratories Ltd. Pharmaceutical compositions of lanthanum carbonate and process for the preparation thereof
CN101732277A (zh) * 2009-12-21 2010-06-16 正大青春宝药业有限公司 一种稳定的西他沙星药用组合物及其制备方法
EP2524689B1 (en) * 2009-12-28 2016-10-05 Nipro Corporation Method for producing donepezil tablets
CA2819460C (en) 2010-12-03 2017-08-01 Takeda Pharmaceutical Company Limited Orally disintegrating tablet
EP2649182A4 (en) 2010-12-10 2015-05-06 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHOD FOR INCREASING AN ERYTHROPOIETIN (EPO) PREPARATION
SG192645A1 (en) 2011-02-17 2013-09-30 Takeda Pharmaceutical Production method of optically active dihydrobenzofuran derivative
KR101877868B1 (ko) * 2011-08-08 2018-07-12 가부시키가이샤산와카가쿠켄큐쇼 아조세미드를 유효성분으로 하는 코팅제제
JP5844573B2 (ja) * 2011-08-10 2016-01-20 共和薬品工業株式会社 ピタバスタチンを含有する錠剤
US8617610B2 (en) 2012-05-21 2013-12-31 Dsm Nutritional Products Ag Compositions and methods for increasing the stability of food product additives
MX2015001416A (es) 2012-07-30 2015-05-08 Meiji Seika Pharma Co Ltd Agente liquido topico para el tratamiento de la dermatofitosis.
ES2638420T3 (es) 2013-04-04 2017-10-20 Daiichi Sankyo Company, Limited Composición sólida de sal de aminocarboxilato
KR102401145B1 (ko) 2015-03-19 2022-05-23 다이이찌 산쿄 가부시키가이샤 착색제를 함유하는 고형 제제

Also Published As

Publication number Publication date
CN107427483A (zh) 2017-12-01
ES2821733T3 (es) 2021-04-27
TWI717339B (zh) 2021-02-01
TW201639553A (zh) 2016-11-16
EP3272346A4 (en) 2018-08-01
EP3513788B1 (en) 2020-07-29
CA2980097C (en) 2019-10-29
KR20170128323A (ko) 2017-11-22
US10603285B2 (en) 2020-03-31
JPWO2016148264A1 (ja) 2017-12-28
EP3437639A1 (en) 2019-02-06
WO2016148264A1 (ja) 2016-09-22
JP6630344B2 (ja) 2020-01-15
BR112017019920B1 (pt) 2023-11-07
CN107427483B (zh) 2021-06-29
EP3272346A1 (en) 2018-01-24
EP3513788A1 (en) 2019-07-24
KR102401145B1 (ko) 2022-05-23
CA2980097A1 (en) 2016-09-22
US20180243223A1 (en) 2018-08-30

Similar Documents

Publication Publication Date Title
BR112017019920A2 (pt) preparação sólida farmacêutica, e, método para estabilização de uma preparação sólida farmacêutica
EA201600457A1 (ru) Фармацевтические композиции, содержащие диметилфумарат
EA201890124A1 (ru) Новые гидроксикислотные производные, способ их получения и фармацевтические композиции, содержащие их
MY190561A (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them
CY1118839T1 (el) Επικαλυμμενη φαρμακευτικη συνθεση που περιεχει ρεγοραφενιμπη
EA201791692A1 (ru) 4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
EA201592055A1 (ru) 11-гидроксилпроизводные желчных кислот и их аминокислотные конъюгаты в качестве модуляторов фарнезоидных х-рецепторов
EA201890123A1 (ru) Новые аминокислотные производные, способ их получения и фармацевтические композиции, содержащие их
EA201501122A8 (ru) Новые агонисты соматостатиновых рецепторов подтипа 4 (sstr4)
EA202091400A1 (ru) Производные пиррола в качестве ингибиторов асс
EA201690888A1 (ru) Новые гетероциклические соединения
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
NZ711343A (en) Sodium salt of (2s, 5r)-6-benzyloxy-7-oxo-1,6-diaza-bicyclo [3.2.1 ] octane-2-carboxylic acid and its preparation
EA201890532A1 (ru) Новые аннелированные бензамиды
EA201690183A1 (ru) Замещенные пиразолопиридинамины
EA201591795A1 (ru) Бицикло[2.2.1]-кислоты в качестве модуляторов рецептора gpr120
WO2015138276A3 (en) Retinoic acid receptor-related orphan receptor modulators and uses thereof
BR112016021471A8 (pt) derivados de ácido acético azaindol e seu uso como moduladores de receptor d2 de prosrtglandina
BR112018007673A2 (pt) ?análogos de epotilona, métodos de síntese, métodos de tratamento e conjugados de fármaco dos mesmos?
NZ764004A (en) Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators
BR112015005560A2 (pt) derivados de macrolídeos, sua preparação e seu uso terapêutico
EA201400444A1 (ru) Производные 2-оксопиперидинила
TR201908937T4 (tr) P38 MAP kinazı inhibe eden indanil üre bileşikleri.
EA201400473A1 (ru) Способ синтеза 3,4-диметоксибицикло[4.2.0]окта-1,3,5-триен-7-карбонитрила и применение для синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/03/2016, OBSERVADAS AS CONDICOES LEGAIS